Britain Courts Anthropic Amid US Defense Department Dispute 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
NEW YORK, Jan. 30, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PixarBio Corporation (OTCMKTS:PXRB) securities (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/pixarbio-corporation. There is no cost or obligation to you.
According to the complaint, PixarBio made false and/or misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) certain assertions in press releases, third party promotional materials, and PixarBio’s Form S-1 lacked accuracy; and (3) as a result, the Company’s public statements were materially false and misleading.
If you suffered a loss in PixarBio you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/pixarbio-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
